MedTrace Logo

Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis, Rheumatoid Arthritis, Joint/Muscle Pain

NCT01961271 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2016-09-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the efficacy of the buprenorphine transdermal patch (Norspan® or Sovenor® transdermal patch) in patients with chronic non-malignant pain of moderate to severe intensity due to osteoarthritis, rheumatoid arthritis, lower back pain and joint/muscle pain, who are not adequately responding to non-opioid painkillers.

Conditions

Interventions

DRUG

Buprenorphine transdermal patch

Please see Arm Description.

Sponsors & Collaborators

  • Mundipharma Korea Ltd

    collaborator INDUSTRY

  • Mundipharma (Hong Kong) Ltd

    collaborator UNKNOWN

  • Mundipharma Distribution GmBH (Philippine Branch)

    collaborator UNKNOWN

  • Mundipharma Pte Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • Hong Kong
  • Philippines
  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01961271 on ClinicalTrials.gov